BGA-1901 is under clinical development by Nexbiome Therapeutics and currently in Phase III for Helicobacter pylori Infections. According to GlobalData, Phase III drugs for Helicobacter pylori Infections have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how BGA-1901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BGA-1901 overview
BGA-1901 is under development for treatment of Helicobacter pylori infections. It is a single strain live biotherapeutic comprising Lactobacillus casei rhamnosus LCR35.
Nexbiome Therapeutics overview
Nexbiome Therapeutics (Nexbiome) focuses on microbiome research. Nexbiome is headquartered in Clermont-Ferrand, France.
For a complete picture of BGA-1901’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
